The University of Arizona, doing business as the Arizona Board of Regents, received a $695,403 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The grant, awarded on Jan 1, 2025, supports research aimed at developing clinically relevant approaches to correct endothelial cell dysfunctions, prevent loss of microvasculature, and slow down progression of lung fibrosis. The key products and services to be delivered under this 4-year grant include:
- Determining whether restoring microvascular integrity via nanoparticle gene therapy can inhibit lung fibrogenesis.
- Defining whether transplantation of FOXF1+CKIT+ endothelial progenitor cells can restore microvascular integrity and inhibit lung fibrosis.
This award leverages the University of Arizona's expertise in cardiovascular research, gene therapy, and cellular therapies to advance scientific understanding and potential therapeutic approaches for pulmonary fibrosis, a condition with significant unmet medical need.
Generated 3/4/25, 4:28 AM